New perspectives in gastric acid suppression: Genetic polymorphisms predict the efficacy of proton pump inhibitors

Digestive Diseases

Volumn 18, Issue 2, 2000, Pages 58-63

  Egan, Laurence ^a   Murray, Joseph ^a  

^a MAYO CLINIC   (United States)

Author keywords

Cytochrome P450; Omeprazole; Pharmacogenetics; Polymorphism; Proton pump

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); CYTOCHROME P450 2C19; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE;

AREA UNDER THE CURVE; DRUG CLEARANCE; DRUG EFFICACY; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN CELL; HUMAN TISSUE; PEPTIC ULCER; POPULATION RISK; PREDICTION; PRIORITY JOURNAL; REVIEW; STOMACH ACID SECRETION;

EID: 0033757987     PISSN: 02572753     EISSN: None     Source Type: Journal    
DOI: 10.1159/000016966     Document Type: Review

References (21)

1. Treatment of Helicobacter pylori infection
2. Meta-analysis of randomized clinical trials comparing lansoprazole with ranitidine or famotidine in the treatment of acute duodenal ulcer
3. Rolling review: Gastro-oesophageal reflux disease
4. Long-term treatment with omeprazole for refractory reflux esophagitis: Efficacy and safety
5. Effect of omeprazole - A gastric proton pump inhibitor - On pentagastrin stimulated acid secretion in man
6. Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole
7. Identification of human liver cytochrome P450 isoforms mediating secondary omeprazole metabolism
8. Oxidative metabolism of omeprazole in human liver microsomes: Co-segregation with S-mephenytoin 4'-hydroxylation
9. Comparison of the kinetic disposition and metabolism of E3810, a new proton pump inhibitor, and omeprazole in relation to S-mephenytoin 4'-hydroxylation status
10. Slow omeprazole metabolizers are also poor S-mephenytoin hydroxylators
11. The hydroxylation of omeprazole correlates with S-mephenytoin metabolism: A population study
12. Disposition kinetics and metabolism of omeprazole in extensive and poor metabolizers of S-mephenytoin 4'-hydroxylation recruited from an Oriental population
13. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans
14. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese
15. A new genetic defect in human CYP2C19: Mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin
16. Pharmacokinetics of omeprazole (a substrate of CYP2C19) and comparison with two mutant alleles, CYP2C19m1 in exon 5 and CYP2C19m2 in exon 4, in Japanese subjects
17. Ethnic and genetic determinants of omeprazole disposition and effect
18. Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations
19. CYP2C19 genotype status and eVect of omeprazole on intragastric pH in humans
20. Effect of genetic diVerences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer
21. Comparison of the interaction potential of a new proton pump inhibitor, E3810, versus omeprazole with diazepam in extensive and poor metabolizers of S-mephenytoin 4'-hydroxylation